Company Overview of Sanaria, Inc.
9800 Medical Center Drive
Rockville, MD 20850
Key Executives for Sanaria, Inc.
Sanaria, Inc. does not have any Key Executives recorded.
Sanaria, Inc. Key Developments
Sanaria, Inc. Announces Publication of Encouraging Results from Malaria Study
Feb 15 17
Sanaria Inc. has announced the publication of encouraging results from a study evaluating the safety and efficacy of PfSPZ Vaccine against plasmodium falciparum via direct venous inoculation in healthy malaria-exposed Malian adult in The Lancet Infectious Diseases journal. Investigators reported that Sanaria PfSPZ Vaccine protected against natural infections of Plasmodium falciparum, the leading cause of malaria deaths and that protection was sustained for the 24 weeks of the study in an area of intense malaria transmission. The study was conducted in Doneguebougou, Mali and was led by Dr. Mahamadou Sissoko of the Malaria Research and Training Center at the University of Science, Techniques and Technologies of Bamako, Mali and by Dr. Sara Healy of the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland. In the Mali study, five doses of PfSPZ Vaccine were administered to 44 subjects and saltwater placebo was given to 44 subjects. Volunteers were followed for six months through the subsequent rainy season to determine the presence of malaria parasites in the blood. While a staggering 93% of the placebo group had one or more infections, only 66% of the vaccinated subjects acquired an infection and in those vaccinated subjects who became infected, the time to infection was delayed. This represents 48% protective efficacy by time-to-event analysis and 29% efficacy by proportional analysis. There were no differences in adverse events between the vaccinated group and the placebo group.
Sanaria Inc. Wins $7,580,374 Federal Contract
Sep 25 15
Sanaria Inc. was awarded a $7,580,374 federal contract set aside for small business by the U.S. Army Medical Research Acquisition Activity for clinical trials and manufacture of malaria vaccines. The place of performance will be in Rockville, Baltimore, and Silver Spring, Maryland.
Sanaria, Inc. Wins $3,499,863 Sole Source Federal Contract
Sep 13 15
Sanaria Inc., Rockville, Maryland, won a $3,499,863 sole source federal contract from the U.S. Army Contracting Command, Natick, Massachusetts, for R&D on improving manufacturing process for PfSPZ malaria vaccine.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries